Cas no 1235141-39-5 (trans-(15S)-Latanoprost)

Technical Introduction: trans-(15S)-Latanoprost trans-(15S)-Latanoprost is a stereoisomer of latanoprost, a prostaglandin F2α analog used primarily in ophthalmology for reducing intraocular pressure (IOP) in glaucoma and ocular hypertension. The (15S)-configuration enhances its pharmacological specificity, potentially improving binding affinity to the FP receptor and optimizing therapeutic efficacy. This isomer demonstrates high purity and stability, ensuring consistent performance in formulations. Its mechanism involves increasing aqueous humor outflow via the uveoscleral pathway. trans-(15S)-Latanoprost is synthesized under stringent conditions to meet pharmaceutical-grade standards, making it suitable for research and drug development. Its selective activity and well-characterized profile support its utility in advancing ophthalmic therapies.
trans-(15S)-Latanoprost structure
trans-(15S)-Latanoprost structure
Product Name:trans-(15S)-Latanoprost
CAS No:1235141-39-5
MF:C26H40O5
MW:432.59280872345
CID:833940
PubChem ID:52193982
Update Time:2025-07-04

trans-(15S)-Latanoprost Chemical and Physical Properties

Names and Identifiers

    • (15S)-Latanoprost
    • trans-(15S)-Latanoprost
    • 15S-5,6-trans-Latanprost
    • trans (15S)-Latanoprost
    • (5E)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3S)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid 1-methylethyl ester
    • AKOS015902101
    • 1235141-39-5
    • J-502636
    • trans Latanoprost
    • (Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
    • propan-2-yl (E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
    • Inchi： 1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3+/t21-,22-,23-,24+,25-/m1/s1
    • InChI Key： GGXICVAJURFBLW-QKMKSKRWSA-N
    • SMILES： O[C@@H]1C[C@@H]([C@H](C/C=C/CCCC(=O)OC(C)C)[C@H]1CC[C@@H](CCC1C=CC=CC=1)O)O

Computed Properties

  • Exact Mass: 432.28757437g/mol
  • Monoisotopic Mass: 432.28757437g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 3
  • Hydrogen Bond Acceptor Count: 5
  • Heavy Atom Count: 31
  • Rotatable Bond Count: 14
  • Complexity: 526
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 5
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 1
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 4.3
  • Topological Polar Surface Area: 87?2

Experimental Properties

  • Density: 1.093±0.06 g/cm3 (20 oC 760 Torr),
  • Solubility: Insuluble (6.1E-3 g/L) (25 oC),

trans-(15S)-Latanoprost Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
L177305-0.25mg
trans-(15S)-Latanoprost
 1235141-39-5
0.25mg
 $ 275.00 2022-06-02
TRC
L177305-1mg
trans-(15S)-Latanoprost
 1235141-39-5
1mg
 $ 1248.00 2023-09-07
TRC
L177305-5mg
trans-(15S)-Latanoprost
 1235141-39-5
5mg
 $ 5980.00 2023-09-07
TRC
L177305-250μg
trans-(15S)-Latanoprost
 1235141-39-5
250μg
 $ 339.00 2023-09-07
TRC
L177305-250μg
trans-(15S)-Latanoprost
 1235141-39-5
250μg
 $339.00 2023-05-18

trans-(15S)-Latanoprost Spectrogram

1H NMR 300 MHz DMSO
1H NMR
13C NMR
13C NMR

trans-(15S)-Latanoprost Related Literature

Additional information on trans-(15S)-Latanoprost

trans-(15S)-Latanoprost: A Comprehensive Overview

trans-(15S)-Latanoprost, with the CAS number 1235141-39-5, is a synthetic analog of prostaglandin F2α (PGF2α) that has gained significant attention in the field of ophthalmology. This compound is primarily used in the treatment of elevated intraocular pressure (IOP) associated with glaucoma and ocular hypertension. The molecule's unique structure and mechanism of action make it a cornerstone in modern glaucoma therapy.

The development of trans-(15S)-Latanoprost was a milestone in drug discovery, as it represents one of the first prostaglandin analogs approved for clinical use. Its chemical structure, characterized by a specific stereochemistry at the 15th carbon, plays a crucial role in its pharmacokinetic and pharmacodynamic properties. Recent studies have further elucidated the role of its stereochemistry in enhancing its efficacy and reducing adverse effects compared to earlier prostaglandin derivatives.

trans-(15S)-Latanoprost works by mimicking the action of endogenous prostaglandins, which are naturally occurring lipid compounds involved in various physiological processes, including the regulation of IOP. The compound achieves its therapeutic effect by increasing uveoscleral outflow, a mechanism that has been extensively studied in recent clinical trials. These trials have demonstrated that trans-(15S)-Latanoprost can reduce IOP by up to 30% in patients with primary open-angle glaucoma (POAG), making it one of the most effective first-line treatments available.

One of the most notable advancements in the study of trans-(15S)-Latanoprost is its ability to target specific receptors within the eye, such as the prostaglandin receptor subtype FP. This receptor selectivity not only enhances its therapeutic efficacy but also minimizes off-target effects, which is a critical factor in ensuring patient safety and compliance. Recent research has also explored the potential of combining trans-(15S)-Latanoprost with other anti-glaucoma agents to achieve additive or synergistic effects, thereby addressing the challenges posed by refractory glaucoma cases.

The pharmacokinetics of trans-(15S)-Latanoprost have been thoroughly investigated, revealing that it has a favorable absorption profile when administered topically. Its rapid onset of action and long duration of effect make it an ideal candidate for once-daily dosing regimens, improving patient adherence to treatment regimens. Moreover, studies have shown that trans-(15S)-Latanoprost exhibits minimal systemic bioavailability, further supporting its safety profile.

In terms of clinical applications, trans-(15S)-Latanoprost has been widely used in both adult and pediatric populations with glaucoma. Its safety profile is well-documented, with common side effects such as ocular hyperemia being mild and transient. However, recent studies have highlighted the importance of monitoring for rare but serious adverse events, such as iris pigmentation changes and eyelash growth abnormalities, particularly in long-term use.

The latest research on trans-(15S)-Latanoprost has also focused on its potential beyond glaucoma treatment. Preclinical studies suggest that it may have neuroprotective properties due to its ability to modulate cellular signaling pathways involved in neuronal survival and axon protection. This opens up new avenues for exploring its role in neurodegenerative diseases associated with optic nerve damage.

In conclusion, trans-(15S)-Latanoprost remains a pivotal drug in the management of glaucoma and ocular hypertension. Its unique mechanism of action, favorable pharmacokinetics, and extensive clinical validation underscore its importance in modern ophthalmology. As research continues to uncover new insights into its therapeutic potential and mechanisms, trans-(15S)-Latanoprost is poised to remain at the forefront of glaucoma therapy for years to come.

1235141-39-5 (trans-(15S)-Latanoprost) Related Products

Recommended suppliers
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Amadis Chemical Company Limited
Zhangzhou Sinobioway Peptide Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Zhangzhou Sinobioway Peptide Co.,Ltd.
Nanjing Jubai Biopharm
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Nanjing Jubai Biopharm
Shanghai Bent Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Jianxing Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen Jianxing Pharmaceutical Technology Co., Ltd.